title: [Organ transplantation and blood transfusion].
abstract: Pretransplant blood transfusion remains a controversial subject and its history can summarize the last 40 years of transplantation. Until 1971, transfusions were widely used in patients awaiting transplantation, especially due to the anemia induced by the chronic renal dysfunction. Then, a noxious effect of preformed anti-HLA antibodies on renal grafts survival was reported and pretransplant transfusions were stopped. Between 1972 and 1977, improvement of renal graft survival in patients who received pretransplant transfusions was noted. Therefore, from 1978 on, a systematic policy of pretransplant transfusions was adopted by almost all centres of transplantation. During the eighties, it was again abandoned for several reasons: absence of graft survival improvement in patients treated by cyclosporine, HLA immunization leading to an increased incidence of acute graft rejection, risk of viral diseases transmission and human recombinant erythropoietin development. The lack of improvement in graft survival for ten years has been leading the transplant community to look for antigen-specific immunosuppressive strategies to achieve transplantation tolerance. Donor-specific transfusion may have clinical benefits, as long-term grafts survival improvement, through modulation of the recipient's cellular immune system and has been recently reconsidered, especially before living donor transplantation. The immunological mechanisms inducing a tolerance-gaining effect of transfusions are still misunderstood, but the recent discovery of immunomodulatory effects of the apoptotic cells present in cellular products could enlighten our comprehension of pretransplant transfusions benefits and could help to develop specific tolerance induction strategies in solid organ transplantation.
authors.affiliation: Néphrologie et transplantation, hôpital Henri-Mondor, AP-HP, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil cedex, France.
authors.forename: M
authors.initials: M
authors.lastname: Matignon
authors.forename: F
authors.initials: F
authors.lastname: Bonnefoy
authors.forename: P
authors.initials: P
authors.lastname: Lang
authors.forename: P
authors.initials: P
authors.lastname: Grimbert
mesh_terms: D000740:Anemia / Q000628:therapy; D000818:Animals; D017209:Apoptosis / Q000276:immunology; D001782:Blood Donors; D001803:Blood Transfusion / Q000706:statistics & numerical data; D006082:Graft Enhancement, Immunologic / Q000379:methods; D006084:Graft Rejection / Q000276:immunology / Q000517:prevention & control; D006085:Graft Survival; D006680:HLA Antigens / Q000276:immunology; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D007518:Isoantibodies / Q000276:immunology; D016030:Kidney Transplantation; D016377:Organ Transplantation / Q000639:trends; D010586:Phagocytes / Q000276:immunology / Q000637:transplantation; D011300:Preoperative Care / Q000009:adverse effects / Q000379:methods / Q000706:statistics & numerical data / Q000639:trends; D016176:T-Lymphocyte Subsets / Q000276:immunology; D014019:Tissue Donors; D065227:Transfusion Reaction; D014181:Transplantation Immunology
chemical_list: D006680:HLA Antigens; D007518:Isoantibodies